Skip to content

US · HUMA · BIOTECHNOLOGY

Humacyte, Inc. (HUMA) intrinsic value and stock valuation

$0.45as of 2026-11-21 · Mkt cap 122.44M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Humacyte, Inc. DCF and intrinsic value

InvestorsCraft values HUMA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from HUMA’s statements →

Humacyte, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Durham, NC 27713 humacyte.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$2.04M+6.5% 5y CAGRd
20192025
Net income
-$-40.83M
20192025
Free cash flow
-$-105.93M
20192025
Total equity
$3.11M-46.5% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$2.04M$0.00$0.00$1.56M$1.26M
Operating income-$-107.44M-$-114.4M-$-100.05M-$-84.58M-$-81.21M
Net income-$-40.83M-$-148.7M-$-110.78M-$-11.96M-$-26.48M
EPSd-$-258.16K-$-1.26M-$-1.07M-$-116.06K-$-662.5K
Operating cash flow-$-105.04M-$-98.12M-$-73.31M-$-71.13M-$-81.19M
Capital expenditure-$-880K-$-1.57M-$-2.28M-$-1.05M-$-220K
Free cash flow-$-105.93M-$-99.69M-$-75.58M-$-72.18M-$-81.41M
Total assets$116.4M$137.9M$128.2M$204.3M$286.5M
Total debt$64.9M$16.5M$57.5M$50.1M$51.2M
Net debt$14.4M-$-28.4M-$-23M-$-99.71M-$-166.32M
Total equity$3.11M-$-52.67M$13.6M$116.9M$122.2M
Cash and short-term investments$50.5M$44.9M$80.5M$151.9M$225.5M
Income statement
20252024202320222021
Revenue$2.04M$0.00$0.00$1.56M$1.26M
Cost of revenue$17.1M$7.19M$76.6M$8.26M$61.3M
Gross profit-$-15.01M-$-7.19M-$-76.55M-$-6.69M-$-60.08M
Research and development expenses$69.3M$88.6M$76.6M$63.3M$61.3M
Selling, general and administrative expenses$31.2M$25.8M$20.4M$22.9M$21.1M
Other expenses-$-8.04M-$-7.19M-$-73.44M-$-8.26M-$-61.34M
Operating expenses$92.4M$107.2M$23.5M$77.9M$21.1M
Cost and expenses$109.5M$114.4M$100.1M$86.1M$82.5M
Interest income$2.59M$4.1M$5.47M$2.63M$20K
Interest expense$11.3M$9.28M$6.6M$6.2M$4.35M
Depreciation and amortization$7.34M$7.19M$7.72M$8.21M$8.24M
Ebitda-$-22.24M-$-132.23M-$-96.46M$2.44M-$-13.89M
Operating income-$-107.44M-$-114.4M-$-100.05M-$-84.58M-$-81.21M
Total other income/expenses, net$66.6M-$-34.3M-$-10.73M$72.6M$54.7M
Income before tax-$-40.83M-$-148.7M-$-110.78M-$-11.96M-$-26.48M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-40.83M-$-148.7M-$-110.78M-$-11.96M-$-26.48M
Weighted average shares outstanding$158.2M$118.5M$103.4M$103.1M$40M
Weighted average diluted shares outstanding$158.2M$118.5M$103.4M$103.1M$40M
Balance sheet
20252024202320222021
Cash and short-term investments$50.5M$44.9M$80.5M$151.9M$225.5M
Net receivables$440K$0.00$0.00$30K$180K
Inventory$13.6M$0.00$0.00$0.00$0.00
Total current assets$67.8M$47.9M$83.3M$154.2M$229.3M
Property, plant and equipment, net$47.7M$38.6M$44.1M$50.1M$57.2M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$210K$0.00$0.00$0.00$0.00
Total non-current assets$48.6M$90M$45M$50.1M$57.2M
Total assets$116.4M$137.9M$128.2M$204.3M$286.5M
Accounts payable$5.4M$4.49M$6.49M$1.59M$2.09M
Short-term debt$2.43M$2.92M$2.56M$10.9M$2.03M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$18.4M$20M$18.4M$19.6M$11.1M
Long-term debt$62.4M$77M$54.9M$39.2M$49.2M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$94.9M$170.6M$96.2M$67.8M$153.3M
Capital lease obligations$29.4M$16.5M$18.9M$21.2M$23.8M
Total liabilities$113.3M$190.5M$114.7M$87.4M$164.4M
Common stock$20K$10K$10K$10K$10K
Retained earnings-$-726.85M-$-686.01M-$-537.31M-$-426.54M-$-414.57M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$3.11M-$-52.67M$13.6M$116.9M$122.2M
Total investments$210K$0.00$0.00$2.11M$8M
Total debt$64.9M$16.5M$57.5M$50.1M$51.2M
Net debt$14.4M-$-28.4M-$-23M-$-99.71M-$-166.32M
Cash flow statement
20252024202320222021
Net income-$-40.83M-$-148.7M-$-110.78M-$-11.96M-$-26.48M
Depreciation and amortization$5.33M$7.19M$7.72M$8.21M$8.24M
Stock-based compensation$9.75M$6.14M$6.83M$6.18M$10.2M
Change in working capital-$-23.39M$310K$6.57M$1.03M-$-560K
Accounts receivable-$-260K$0.00$30K$140K-$-60K
Inventory-$-21.83M$0.00$0.00$0.00$0.00
Accounts payable$970K-$-1.96M$4.81M-$-510K-$-200K
Net cash provided by operating activities-$-105.04M-$-98.12M-$-73.31M-$-71.13M-$-81.19M
Investments in property, plant and equipment-$-880K-$-1.57M-$-2.28M-$-1.05M-$-220K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-880K-$-1.57M-$-170K$4.84M-$-8.22M
Common stock issued$113.4M$45.9M$570K$540K$600K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$61.5M$114.2M$4.51M-$-1.45M$267M
Net change in cash-$-44.44M$14.5M-$-69.18M-$-67.73M$177.6M
Cash at end of period$50.9M$95.3M$80.6M$149.8M$217.5M
Operating cash flow-$-105.04M-$-98.12M-$-73.31M-$-71.13M-$-81.19M
Capital expenditure-$-880K-$-1.57M-$-2.28M-$-1.05M-$-220K
Free cash flow-$-105.93M-$-99.69M-$-75.58M-$-72.18M-$-81.41M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Humacyte, Inc.

        Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.

        CEO
        Laura E. Niklason
        Employees
        184
        Beta
        2.52

        Explore

        Frequently asked questions

        What is the intrinsic value of Humacyte, Inc. (HUMA)?

        InvestorsCraft does not currently publish an intrinsic value for HUMA. How the IC value is calculated.

        Is HUMA undervalued?

        InvestorsCraft does not publish an undervaluation signal for HUMA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.